Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.International journal of cancer · 2022
   Trial
2. Fatty acid synthase regulates invasion and metastasis of colorectal cancer via Wnt signaling pathway.Cancer medicine · 2016
   Article
3. Comment on: "Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review".PharmacoEconomics · 2016
   Article

Corrections and comments

• Commented on by
  Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.2015
• Commented on by
  Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.2015
• Comment on
  Can money really be no object when cancer care is the subject?2015

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as